NCT06540443View on ClinicalTrials.gov

Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Head and Neck Squamous Cell CarcinomaLymph Node Metastasis
Interventions
DRUG

MPB-2043 of 0.5 mg/kg

Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.

DRUG

MPB-2043 of 1.0 mg/kg

Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.

DRUG

MPB-2043 of 2.0 mg/kg

Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.

DRUG

MPB-2043 of 3.0 mg/kg

Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.

Trial Locations (1)

100

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

lead

MegaPro Biomedical Co. Ltd.

INDUSTRY